What did @cheyd25 actually say?
Honestly? Almost nothing medically useful. The transcript is song lyrics, not health commentary. What the video actually communicates is in the caption: a 42-pound weight loss (211 to 169 lbs) attributed to a monthly semaglutide supply from a brand called Freya, with a bio link that reads like an affiliate pitch. That framing is doing a lot of work.
The post functions as a testimonial-style advertisement. There are no spoken claims about how semaglutide works, what the treatment protocol looked like, whether a clinician was involved, or what other factors contributed to the weight loss. The caption is the message, and the message is: use this product, get these results. That deserves scrutiny.
Does the science back up a 42-pound loss on semaglutide?
A 42-pound loss is plausible on semaglutide, but it is not typical, and context matters enormously. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean weight loss of about 14.9% of body weight over 68 weeks with 2.4 mg weekly semaglutide plus lifestyle intervention. For someone starting at 211 lbs, that math works out to roughly 31 lbs on average, meaning 42 lbs is above average but within the range of reported outcomes.
What the video omits is just as important. The STEP trials required consistent subcutaneous injections, dietary changes, and clinical oversight. Results without those elements are likely to be worse. Wilding et al. also showed that most participants regained weight after stopping the drug (Wilding et al., 2022, Diabetes, Obesity and Metabolism). A number on a scale without timeline or protocol is not a reproducible result. It is a before-and-after photo with a brand tag.
What did they get wrong, or right?
There are no spoken medical claims to fact-check in the transcript, which is almost the problem. The video does not get the science wrong because it does not attempt the science. What it gets wrong is the framing.
Presenting dramatic weight loss alongside a direct product link, with no disclosure of whether this is a paid partnership, no mention of medical supervision, and no acknowledgment of side effects, is misleading by omission. The FDA has specific guidelines about testimonial advertising for prescription drugs. Semaglutide is a prescription medication. Promoting it via a social media bio link, regardless of what Freya's own compliance looks like, raises real questions about how viewers are meant to interpret and act on this content.
GLP-1 side effects are not trivial. Nausea, vomiting, gastroparesis, and pancreatitis risk are documented in the prescribing information and in published literature (Bethel et al., 2018, Lancet Diabetes and Endocrinology). None of that appears here.
What should you actually know?
If you are considering semaglutide for weight loss, the evidence base is real and reasonably strong. The STEP program and SELECT trial data (Lincoff et al., 2023, New England Journal of Medicine) support its use in appropriate candidates. But appropriate candidates are identified through clinical evaluation, not a TikTok bio link.
Compounded semaglutide, which is what many telehealth platforms were dispensing during the FDA shortage period, is not the same as FDA-approved Wegovy or Ozempic. The FDA has been explicit about this. Compounded versions are not evaluated for safety, efficacy, or quality by the FDA. That is not a minor footnote.
- Always confirm whether a telehealth platform is LegitScript-certified before purchasing any prescription medication online.
- A dramatic weight loss testimonial tells you nothing about what happened clinically or whether it is replicable for you.
- Side effect disclosure is not optional. If a platform or creator is not mentioning GI effects, injection site reactions, or contraindications, that is a gap worth noticing.